The impact of viremia on organ failure, biomarkers and mortality in a Swedish cohort of critically ill COVID-19 patients

Josef D Järhult, Michael Hultström, Anders Bergqvist, Robert Frithiof, Miklos Lipcsey, Josef D Järhult, Michael Hultström, Anders Bergqvist, Robert Frithiof, Miklos Lipcsey

Abstract

The spread of virus via the blood stream has been suggested to contribute to extra-pulmonary organ failure in Coronavirus disease 2019 (COVID-19). We assessed SARS-CoV-2 RNAemia (RNAemia) and the association between RNAemia and inflammation, organ failure and mortality in critically ill COVID-19 patients. We included all patients with PCR verified COVID-19 and consent admitted to ICU. SARS-CoV-2 RNA copies above 1000/ml measured by PCR in plasma was defined as RNAemia and used as surrogate for viremia. In this cohort of 92 patients 59 (64%) were invasively ventilated. RNAemia was found in 31 patients (34%). Hypertension and corticosteroid treatment was more common in patients with RNAemia. Extra-pulmonary organ failure biomarkers and the extent of organ failure were similar in patients with and without RNAemia, but the former group had more renal replacement therapy and higher mortality (26 vs 16%; 35 vs 16%, respectively, p = 0.04). RNAemia was not an independent predictor of death at 30 days after adjustment for age. SARS-CoV2 RNA copies in plasma is a common finding in ICU patients with COVID-19. Although viremia was not associated with extra pulmonary organ failure it was more common in patients who did not survive to 30 days after ICU admission.Trial registration: ClinicalTrials NCT04316884.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
SARS-CoV-2 RNA levels in plasma on the ICU day of sampling. Mann–Whitney test was used to compare RNA levels on ICU day 1–2 and ICU day 5–7. The p-value denotes difference in RNA copies from ICU days 1–2 to 5–7.
Figure 2
Figure 2
Odds ratios from logistic regression assessing the association between age, crude and age adjusted RNAemia in plasma, and risk of organ support and death. RNAemia was defined as SARS-CoV-2 RNA copies > 1000/ml plasma. * denotes p 

References

    1. Richardson S, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 doi: 10.1001/jama.2020.6775.
    1. Eriksson O, et al. Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients. Thromb. Haemost. 2020 doi: 10.1055/s-0040-1715835.
    1. Gupta A, et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 2020;26:1017–1032. doi: 10.1038/s41591-020-0968-3.
    1. Tepasse PR, et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br. J. Haematol. 2020;190:185–188. doi: 10.1111/bjh.16896.
    1. Vivanti AJ, et al. Transplacental transmission of SARS-CoV-2 infection. Nat. Commun. 2020;11:3572. doi: 10.1038/s41467-020-17436-6.
    1. Kodama T, et al. Serial serum SARS-CoV-2 RNA results in two COVID-19 cases with severe respiratory failure. J. Infect. Chemother. 2020;26:1220–1223. doi: 10.1016/j.jiac.2020.07.003.
    1. Chen W, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg. Microbes. Infect. 2020;9:469–473. doi: 10.1080/22221751.2020.1732837.
    1. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. . Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Duan K, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl. Acad. Sci. USA. 2020;117:9490–9496. doi: 10.1073/pnas.2004168117.
    1. Patterson, B. K. et al. Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19. medRxiv, 10.1101/2020.05.02.20084673 (2020).
    1. Veyer D, et al. Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa1196.
    1. Corman VM, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25:1. doi: 10.2807/1560-7917.ES.2020.25.3.2000045.
    1. CDC. Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes. (2020).
    1. Moreno RP, et al. SAPS 3–From evaluation of the patient to evaluation of the intensive care unit: Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intens. Care Med. 2005;31:1345–1355. doi: 10.1007/s00134-005-2763-5.
    1. Vincent JL, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–710. doi: 10.1007/BF01709751.
    1. Section 2: AKI Definition. Kidney inter., Suppl.2, 19–36 (2012).
    1. Chen W, et al. Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. J. Med. Microbiol. 2004;53:435–438. doi: 10.1099/jmm.0.45561-0.
    1. Bermejo-Martin JF, et al. Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. Crit. Care. 2020;24:691. doi: 10.1186/s13054-020-03398-0.
    1. Frithiof R, Bergqvist A, Jarhult JD, Lipcsey M, Hultstrom M. Presence of SARS-CoV-2 in urine is rare and not associated with acute kidney injury in critically ill COVID-19 patients. Crit. Care. 2020;24:587. doi: 10.1186/s13054-020-03302-w.
    1. Reilev M, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int. J. Epidemiol. 2020 doi: 10.1093/ije/dyaa140.
    1. Palmieri L, et al. Clinical Characteristics of Hospitalized Individuals Dying With COVID-19 by Age Group in Italy. J. Gerontol. A Biol. Sci. Med. Sci. 2020;75:1796–1800. doi: 10.1093/gerona/glaa146.
    1. Xu D, et al. Relationship Between serum SARS-CoV-2 nucleic acid(RNAemia) and Organ Damage in COVID-19 Patients: A Cohort Study. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa1085.
    1. Hagman K, et al. SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa1285.
    1. Prebensen C, et al. SARS-CoV-2 RNA in plasma is associated with ICU admission and mortality in patients hospitalized with COVID-19. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa1338.
    1. Zangrillo A, et al. Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. Crit. Care Resuscit. J. Australas. Acad. Crit. Care Med. 2020;22:200–211.
    1. Cobos-Siles M, et al. Cause-specific death in hospitalized individuals infected with SARS-CoV-2: more than just acute respiratory failure or thromboembolic events. Intern Emerg. Med. 2020;15:1533–1544. doi: 10.1007/s11739-020-02485-y.
    1. Group, R. C. et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med10.1056/NEJMoa2021436 (2020).

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する